Scientists have developed an injectable or catheter-administered hydrogel with enhanced capabilities for treating hepatocellular carcinoma, a deadly form of liver cancer. This drug-eluting hydrogel can provide sustained, pH-dependent drug co-delivery and has capabilities for promoting anti-tumor immune responses. This reduces tumor cell proliferation and growth and offers a more efficient means of enabling tumor cell death.
